Overview

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure. The study will investigate the dose response relationship for the combinations and monotherapies.
Phase:
Phase 2
Details
Lead Sponsor:
LG Life Sciences
Treatments:
Lercanidipine
Valsartan